# GSK partners with SBP Group to support bepirovirsen launch in China

- Link: https://www.directorstalkinterviews.com/gsk-partners-with-sbp-group-to-support-bepirovirsen-launch-in-china/4121251030
- Published: 2026-05-11T07:39:14+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
[LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l),
NYSE: GSK) has announced that it has entered into an exclusive strategic collaboration
with Sino Biopharmaceutical, (SBP Group), through its subsidiary Chia Tai Tianqing
Pharmaceutical Group Co., Ltd. (CTTQ), to accelerate bepirovirsen in mainland China
at launch. Bepirovirsen is a potential first-in-class treatment for chronic hepatitis
B (CHB) under priority regulatory review in China. CTTQ is a market leader in hepatitis
B in China with one of the country’s most comprehensive liver disease portfolios
and a broad commercial footprint covering more than 5,000 medical centres across
care settings. CTTQ has played a significant role in advancing the diagnosis and
treatment of hepatitis B in China. 

·   Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B,
under priority regulatory review in China

·   Chronic hepatitis B affects 75 million people in China and is a national health
priority

·   Collaboration provides scaled access to over 5,000 medical centres in China 
at launch

·   Agreement gives GSK the ability to review SBP Group’s early-stage pipeline for
potential collaboration opportunities

The collaboration combines GSK innovation with CTTQ’s local scale and in-market 
execution to reach more patients, more quickly. Under the agreement, CTTQ will be
responsible for importation, distribution, hospital access, and promotional and 
non-promotional activities for bepirovirsen in mainland China. GSK will remain the
marketing authorisation holder and retain responsibility for regulatory, quality,
pharmacovigilance and global medical strategy. The agreement also grants GSK the
ability to review certain early-stage pipeline assets of the SBP Group to evaluate
the potential for collaboration opportunities outside China.

> **Mike Crichton, President International, GSK, said:** “Chronic hepatitis B affects
> 75 million people in China**^(1)** and is a leading cause of liver cancer in the
> country.**^(2)** By combining GSK’s innovation with CTTQ’s extensive local scale
> and execution, we want to reach more patients, deliver greater impact, and directly
> address one of China’s most pressing healthcare priorities.”

Chronic hepatitis B is a national health priority in China. The latest National 
Action Plan for the Prevention and Treatment of Viral Hepatitis (2025-2030) has 
set out functional cure as a treatment goal for Hepatitis B. Functional cure occurs
when the hepatitis B virus DNA and viral protein – hepatitis B surface antigen (
HBsAg) – are undetectable in the blood for at least 6 months after stopping all 
treatment. Functional cure is associated with a meaningful reduction in the risk
of long-term complications, including liver cancer.^(3)

Bepirovirsen was granted Breakthrough Therapy designation in China in August 2021
and accepted for Priority Review in April 2026. The regulatory submission is supported
by positive results from the B-Well 1 and B-Well 2 phase III trials, which demonstrated
statistically significant and clinically meaningful functional cure rates.

**Collaboration terms**

Under the terms of the agreement, CTTQ will purchase bepirovirsen from GSK under
agreed supply terms for an initial term of 5.5 years. The term may be extended thereafter
by mutual agreement. GSK will book sales of bepirovirsen supplied to CTTQ through
the collaboration.

GSK also has the ability to review certain early-stage pipeline assets of the SBP
Group to evaluate potential collaboration opportunities outside China.

**About chronic hepatitis B**

Hepatitis B is a viral infection that can cause both acute and chronic liver disease.
Chronic Hepatitis B (CHB) occurs when the immune system is unable to clear the virus,
resulting in long-lasting infection. CHB affects more than 250 million people worldwide.
Each year, the disease causes approximately 1.1 million deaths.**^(1)** Many patients
often require lifelong antiviral therapy for viral suppression; making functional
cure a critical goal in disease management.

CHB remains a significant public health challenge in China, affecting an estimated
75 million people and causing approximately 450,000 deaths annually.**^(1)** 84.4%
of patients with liver cancer in China are associated with CHB infection.**^(2)**
Functional cures are associated with a significant reduction in the risk of long-
term liver complications, including liver cancer.**^(3)**

**About bepirovirsen**

Bepirovirsen is a triple action investigational antisense oligonucleotide (ASO),
designed to inhibit the replication of viral DNA in the body, suppress the level
of hepatitis B surface antigen (HBsAg) in the blood, and stimulate the immune system
to increase the chances of a durable and sustained response. 

GSK licensed bepirovirsen from Ionis and collaborated with them on its development.
Bepirovirsen has been recognised by global regulatory authorities for its innovation
and potential to address significant unmet need in hepatitis B, with Priority Review,
Fast Track and Breakthrough Designations from the US FDA, Priority Review and Breakthrough
Therapy designation in China and SENKU designation in Japan.

Share on:
